In small cell lung cancer (SCLC), approximately 80% of patients have high DLL3 expression, and Rovalpituzumab tesirine has demonstrated an ORR of 38% in patients with high DLL3 expression[69-72]. The gene discussed is DLL3; the disease is small cell lung carcinoma.